Dr Marwan Kwok MB ChB, MRCP (UK), PhD

Dr Marwan Kwok

Institute of Cancer and Genomic Sciences
NIHR Clinical Lecturer

Contact details

Institute of Cancer and Genomic Sciences
Institute for Biomedical Research West
Medical School
University of Birmingham
Birmingham B15 2TT

Dr Marwan Kwok is a National Institute for Health Research (NIHR) funded academic clinical lecturer. He is also a specialist registrar in haematology at Queen Elizabeth Hospital Birmingham and the West Midlands deanery.

His current research focuses on lymphoid malignancies, particularly chronic lymphocytic leukaemia.  His research is conducted within Professor Tatjana Stankovic’s haematopoietic malignancies research group at the University of Birmingham, and at the Centre for Clinical Haematology at Queen Elizabeth Hospital. His work also benefits from close collaboration with Professor Peter Hillmen at Leeds Cancer Centre, and with the Centre for Computational Biology in Birmingham.

He conducts translational research with the aim to improve clinical outcome through novel insights into disease biology and therapeutics. His research interests include the natural history and clinical heterogeneity of lymphoid malignancies, as well as novel therapeutic targets and minimal residual disease in these conditions. He held a Leukaemia and Lymphoma Research clinical research training fellowship from 2014 to 2017, and was a EHA-ASH Translational Research Training in Hematology (TRTH) 2015 participant. He has authored manuscripts in New England Journal of Medicine, Blood and Leukemia. In addition, he was awarded the UK CLL Forum Hamblin Prize (March 2016) and the Royal College of Pathologists specialty research medal (March 2017) for his work. 


  • PhD, University of Birmingham, 2018
  •  MRCP (UK), Royal Colleges of Physicians, 2013
  •  MB ChB, University of Leeds, 2009
  •  BSc (Hons, Class I), University College London, 2006


MB ChB and BMedSc programmes


Current research themes:

  1. Natural history and clinical heterogeneity of lymphoid malignancies.
  2. Novel therapeutic approaches for haematological malignancies.
  3. Minimal residual disease in lymphoid malignancies.

The research groups and centres that Dr Kwok has involvement with can be found at the following links:

Cancer Genetics & Cancer Biology http://www.birmingham.ac.uk/research/activity/cancer-genomics/research/genetics-biology.aspx

Prof Tatjana Stankovic’s profile page http://www.birmingham.ac.uk/staff/profiles/cancer-genomic/stankovic-tatjana.aspx

Birmingham CLL research group  http://www.birmingham.ac.uk/research/activity/immunology-immunotherapy/research/cll/index.aspx


Kwok M, Rawstron AC, Varghese A, Evans PAS, O’Connor SJM, Doughty C, Newton DK, Moreton P, Hillmen P. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016; 128:2770-2773

Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood. 2016; 127:582-595  

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T. USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status. Blood. 2017; 130:156-166

Davies NJ, Kwok M, Gould C, Oldreive CE, Mao J, Parry H, Smith E, Agathanggelou A, Pratt G, Taylor AMR, Moss P, Griffiths M, Stankovic T. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget. 2017; 8:44749-44760

Rawstron AC, Bennett F, O’Connor SJM, Kwok M, Fenton JAL, Plummer M, Tute R, Richards SJ, Jack AS, Hillmen P. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. New Engl J Med. 2008; 359:575-583

Chuah C, Barnes DJ, Kwok M, Corbin A, Deininger MWN, Druker BJ, Melo JV. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukemic cells. Leukemia. 2005; 19:1896-1904

Kwok M, Stankovic T. Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer. In Johnson DE (ed), Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Elsevier Publishing Company. 2018; p. 204-231

View all publications in research portal